CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $20.00, for a total value of $50,000.00. Following the completion of the sale, the chief financial officer now directly owns 12,126 shares of the company’s stock, valued at approximately $242,520. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Debanjan Ray also recently made the following trade(s):

  • On Monday, October 2nd, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $18.10, for a total value of $45,250.00.
  • On Friday, September 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $17.17, for a total value of $42,925.00.
  • On Wednesday, August 9th, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $37,500.00.

Shares of CytomX Therapeutics, Inc. (NASDAQ CTMX) opened at $20.23 on Monday. CytomX Therapeutics, Inc. has a twelve month low of $9.85 and a twelve month high of $24.67.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The business had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million. equities analysts forecast that CytomX Therapeutics, Inc. will post -1.46 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/06/insider-selling-cytomx-therapeutics-inc-ctmx-cfo-sells-50000-00-in-stock.html.

Several research firms have recently commented on CTMX. BidaskClub downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a report on Tuesday, August 8th. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Finally, Wedbush set a $37.00 price objective on CytomX Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $31.88.

A number of institutional investors have recently made changes to their positions in the business. American Century Companies Inc. lifted its holdings in CytomX Therapeutics by 185.3% during the 3rd quarter. American Century Companies Inc. now owns 169,799 shares of the biotechnology company’s stock valued at $3,085,000 after purchasing an additional 110,283 shares during the last quarter. California State Teachers Retirement System increased its position in CytomX Therapeutics by 27.8% during the 2nd quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock worth $797,000 after buying an additional 11,200 shares during the period. The Manufacturers Life Insurance Company increased its position in CytomX Therapeutics by 36.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,529 shares of the biotechnology company’s stock worth $365,000 after buying an additional 6,342 shares during the period. Redmile Group LLC increased its position in CytomX Therapeutics by 2.4% during the 2nd quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock worth $10,825,000 after buying an additional 16,500 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in CytomX Therapeutics during the 2nd quarter worth $174,000. 60.02% of the stock is owned by institutional investors and hedge funds.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.